UNSPSC 51152075: Vecuronium bromide

This classification denotes a muscle relaxant with the molecular formula C34H57N2O4.Br, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7E4PHP5N1D, chemically known as 5alpha-androstan-3alpha,17beta-diol, 16beta-pipecolinio-2beta-piperidino-,bromide,diacetate but more generally known as vecuronium bromide, which bears US NIH Compound Identifier 39764. European Medicines Agency schedules Vecuronium bromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00029MIG.

UNSPSC 51152075 Vecuronium bromide is a Commodity code nominally tied to a specific pharmaceutical compound, but the recent state and local opportunities posted under it show no direct procurement of vecuronium bromide itself. Instead, the tagged solicitations cover naloxone (an opioid antagonist) and direct-to-manufacturer prescription programs through state health agencies. The mismatch signals that this code sees little relevant recent activity aligned to its stated scope. When state and local procurement offices do use pharmaceutical-specific commodity codes, they typically source through group purchasing organizations, cooperative contracts, or state health department formularies rather than direct solicitation; vecuronium bromide in particular would ordinarily flow through hospital pharmacy systems or anesthesia service contracts under broader pharmaceutical or medical-supply families rather than standalone commodity buys.

The two recent opportunities tagged to this code—Seminole County, Florida's naloxone and drug deactivation systems IFB (due July 26, 2023) and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026)—appear to have been miscoded. Neither addresses vecuronium bromide directly; the Seminole County buy targets naloxone specifically for opioid overdose response, and the Texas HHS RFI explores structural changes to pharmacy benefit administration rather than individual drug procurement. Activity under this code does not support a pursue recommendation at this time absent a corrected scope or recent opportunities genuinely soliciting vecuronium bromide supply.